AbbVie Inc (ABBV)vsPrecipio Inc (PRPO)
ABBV
AbbVie Inc
$263.96
-0.02%
HEALTHCARE · Cap: $454.36B
PRPO
Precipio Inc
$26.46
+0.08%
HEALTHCARE · Cap: $47.33M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 236631% more annual revenue ($64.39B vs $27.20M). ABBV leads profitability with a 9.8% profit margin vs -4.5%. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
PRPO
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.5%
Fair Value
$152.16
Current Price
$263.96
$111.80 premium
Intrinsic value data unavailable for PRPO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Conservative balance sheet, low leverage
Revenue surging 24.2% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -2.7% — below average capital efficiency
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : PRPO
The strongest argument for PRPO centers on Debt/Equity, Revenue Growth. Revenue growth of 24.2% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : PRPO
The primary concerns for PRPO are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while PRPO is a growth play — different risk/reward profiles.
PRPO carries more volatility with a beta of 1.33 — expect wider price swings.
PRPO is growing revenue faster at 24.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 30/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Precipio Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Precipio, Inc., a cancer diagnostic and reagent technology company, provides diagnostic products and services in the United States oncology market. The company is headquartered in New Haven, Connecticut.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?